TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus and on oral or parenteral hypoglycemic therapy for at least 1 month.~* History of Coronary Artery Disease with or without other types of vascular disease (such as peripheral vascular disease).~* Taking Aspirin 75-325 mg/day for at least 1 week prior to randomization.~* Between the ages of 18-74 years old.~* If a woman of child bearing age, must not be pregnant and must agree to use reliable method of birth control during the duration of the study.~Exclusion Criteria:~* Thienopyridine therapy within 30 days or have a defined need for thienopyridine treatment.~* Coronary Artery Bypass Graft (CABG) or Percutaneous Coronary Intervention (PCI) with no stent placed within 30 days.~* Planned coronary revascularization~* Hemoglobin A1c (HbA1c) \> or equal to 10 mg/dL within the last 3 months.~* Received fibrolytic therapy \<24 hours prior to randomization.~* Received non-fibrin-specific fibrinolytic therapy \<48 hours prior to randomization.~* At risk of bleeding.~* History of ischemic stroke, transient ischemic attack (TIA), intercranial neoplasm, arteriovenous malformation, or aneurysm.~* Body weight \<60 kilograms (kg).~* International Normalized Ratio (INR) \>1.5, platelet count \<100,000/mm3, or anemia (hemoglobin \<10 gm/dL) within 1 week of study entry.~* Are receiving or will receive oral anticoagulation or antiplatelet treatment therapy.~* Are being treated with daily non-steroidal anti-inflammatory drugs (NSAIDS).~* Are pregnant, breast-feeding or plan to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: EXPERIMENTAL): Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.
- Clopidogrel (Type: ACTIVE_COMPARATOR): Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-OX40 Antibody in Head and Neck Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with treatment naive, resectable, stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx who are candidates for definitive surgical resection followed by standard risk adapted adjuvant therapy.~* Histologic or cytologic diagnosis of a primary OHNSCC with no radiological evidence of metastatic disease is acceptable. Patients with bone or cartilage invasion and any T or N stage are acceptable.~* Patients with oral cavity primaries will be managed using conventional transoral or transcervical techniques; oropharynx or hypopharynx tumor will be managed with transoral robotic surgery; and larynx tumors (T3/T4 with thyroid cartilage invasion) will be managed by either total laryngectomy or larynx preservation surgery.~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2~* Laboratory values (performed within 28 days prior to enrollment) within protocol defined range~* Ability to give informed consent and comply with the protocol. Patients with a history of psychiatric illness must be judged able to understand the investigational nature of the study and the risks associated with the therapy.~* No active gastrointestinal bleeding.~* Anticipated lifespan greater than 12 weeks.~Exclusion Criteria:~* Locoregionally unresectable or Metastatic disease (stage IVB)~* Active infection.~* Active autoimmune disease including patients with Inflammatory Bowel Disease as determined by an autoimmune questionnaire.~* Previous treatment with mouse monoclonal antibodies~* Need for chronic maintenance oral steroids \> 5mg prednisone daily equivalent.~* Any medical or psychiatric condition that in the opinion of the investigator would preclude compliance with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Anti-OX40 antibody administration 3 weeks prior to surgical resection
- Group 2 (Type: EXPERIMENTAL): Anti-OX40 antibody administration 2 weeks prior to surgical resection
- Group 3 (Type: EXPERIMENTAL): Anti-OX40 antibody administration 1 week prior to surgical resection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hematologic malignancies including myelodysplastic syndrome (MDS), who are at a high risk of complications after myeloablative transplantation~* Patients have a donor (both related and unrelated) who are mismatched according to protocol criteria~* 18 years of age or older~* Performance status 0-2~* Life expectancy of \> 100 days~* Female subject is either post-menopausal or sterilized or willing to use an acceptable form of birth control~* Male subject agrees to use an acceptable form of birth control~Exclusion Criteria:~* Evidence of HIV infection~* Total bilirubin \> 2.0mg/dl that is due to hepatocellular dysfunction~* Aspartate aminotransferase (AST) \> 90~* Known active hepatitis B or C~* Serum creatinine \> 2.0~* Greater than or equal to Grade 2 peripheral neuropathy within 21 days of enrollment~* Prior allogeneic stem cell transplant~* Patients with myeloproliferative disease (e.g. myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia)~* Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV hear failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities~* Hypersensitivity to Velcade, boron or mannitol~* Pregnant or breast feeding~* Patient has received other investigational drugs 14 days before enrollment~* Serious medical or psychiatric illness~* Another active solid tumor malignancy at the time of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bortezomib/Tacrolimus/Methotrexate post HSCT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient meets protocol specified criteria for constipation~* Patient has successfully completed study requirements with no clinically relevant findings for physical exam, ECG, laboratory tests and colonoscopy as applicable~Exclusion Criteria:~* Medical history or medical condition that would not make the patient a good candidate for the study or limit the patient´s ability to complete the study~* Patient reports loose stools~* Patient has IBS with pain/discomfort as predominant symptom~* Patient needs medications prohibited as specified in the protocol

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A3309 low dose (Type: EXPERIMENTAL): Administered once daily for the duration of the study
- A3309 intermediate dose (Type: EXPERIMENTAL): Administered once daily for the duration of the study.
- A3309 high dose (Type: EXPERIMENTAL): Administered once daily for the duration of the study
- Placebo (Type: PLACEBO_COMPARATOR): Administered once daily for the duration of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent must be obtained prior to any screening procedures.~2. Patient (male or female) ≥ 18 years of age.~3. Escalation: Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1 who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists.~4. Expansion: Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have progressed despite standard therapy following their last prior therapy or are intolerant to standard therapy and fit into one of the following groups: Group 1: NSCLC resistant to anti-PD-1/PD-L1; Group 2: TNBC; Group 3: HCC; Group 4: MSS-CRC; Group 5: pancreatic; Group 6 ccRCC resistant to anti-PD-1/PD-L1.~   Resistance to anti-PD-1/PD-L1 therapy is defined as: Documented progressive disease occurring while on/or within 6 months after anti-PD-1 and/or anti-PD-L1 agent (single or combination) received as the last therapy prior to enrollment.~5. ECOG Performance Status ≤ 2.~6. Patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy. Patient must be willing to undergo a new tumor biopsy at screening, and during therapy on this study. Exceptions may be made on a case by case basis after documented discussion with Novartis.~Exclusion Criteria:~1. History of severe hypersensitivity reactions to study treatment ingredients or other monoclonal antibodies and components of study drug.~2. Patients with active, known or suspected autoimmune disease. Note: Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.~3. HIV infection.~4. Active HBV or HCV infection.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NIS793 (Type: EXPERIMENTAL): None
- NIS793 + PDR001 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Of SU14813 In Patients With Advanced Solid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a histologically proven advanced solid malignancy for which no recognized therapy was available or for which standard therapy had failed~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Serum albumin ≥3.0 g/dL and adequate haemopoietic, renal and liver function~Exclusion Criteria:~* Chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy or an investigational agent within 4 weeks before the start of study treatment~* Subjects had to have recovered from all prior treatment toxicities, except alopecia, and from any major surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SU014813 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The following are general criteria; more specific conditions are included in the study protocol:~* Subjects with advanced heart failure symptoms (NYHA Class IIIB or IV) who are:~  * On optimal medical management and are failing to respond; or~ * In Class III or Class IV heart failure and dependent on IABP and/or inotropes; or~ * Treated with ACE inhibitors or beta-blockers and found to be intolerant.~* Ineligible for cardiac transplant~* VO2max \<=14 ml/kg/min~* LVEF \<=25%~Exclusion Criteria:~The following are general criteria; more specific conditions are included in the study protocol:~* Evidence of, or risk factors for end-organ dysfunction that would make LVAS implantation futile~* Existence of factors that would adversely affect patient survival or function of the LVAS~* Intolerance to anticoagulant or antiplatelet therapies.~* Existence of any ongoing mechanical circulatory support other than intra-aortic balloon counterpulsation.~* Participation in any other clinical investigation that is likely to confound study results or affect study outcome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HeartMate II (Type: EXPERIMENTAL): Implantation of HeartMate II LVAS
- HeartMate XVE (Type: ACTIVE_COMPARATOR): Implantation of HeartMate XVE LVAS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Varenicline Observational Investigation In The Cessation of Smoking

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patients enrolled should be of legal adult age who regularly smoke and of which the main tobacco product is cigarettes.~* The patients must be willing to make an attempt to stop smoking.~Exclusion Criteria:~* All patients enrolled should meet the usual prescribing criteria for varenicline as per SmPC and should be entered into the trial at the Investigators discretion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. Non-interventional (Type: None): Patients prescribed varenicline in a non interventional manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be a hospitalized male or female subject between birth (\> 37 weeks gestational age) and \< six (6) months of age.~* Have a clinical indication of pain or fever.~* Have written informed consent provided by legal parent, guardian, or authorized agent prior to participation in the study or performance of any study-only related procedures.~Exclusion Criteria:~* Have inadequate intravenous access.~* Have an uncorrected ductus dependent congenital heart disease.~* Have any history of allergy or hypersensitivity to non-steroidal anti-inflammatory drug or aspirin.~* Have a current history of uncorrected hypovolemia or acute renal disease.~* Have a current history of acute liver disease.~* Have received NSAID, acetaminophen, or aspirin drug therapy within four hours prior to dosing. Have received another investigational drug within the past 30 days.~* Be otherwise unsuitable for the study, in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Ibuprofen (Type: EXPERIMENTAL): Ibuprofen, 10 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: START-J: SiTAgliptin in eldeRly Trial in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with type 2 diabetes who are oral hypoglycemic agent naive or, α-glucosidase inhibitor or biguanide monotherapy (to be washed out 4 weeks prior to randomization)~2. Signed informed consent obtained before any trial-related activities~3. Treatment with diet and exercise for 12 weeks and longer at screening~4. Age =\>60 y.o.~5. Male and Female~6. HbA1c 6.9%=\< \<8.9%~Exclusion Criteria:~1. Active proliferative retinopathy or maculopathy requiring treatment~2. Liver dysfunction (\>x2 of upper normal limit), moderate or severe renal dysfunction(serum Cr\>1.5mg/dL in male, Cr\>1.3mg/dL in female, eGFR\<30), severe cardiac disease (NYHA III or IV), malignancy or uncontrolled hypertension (treated or untreated) as judged by the Investigator~3. Mental incapacity (including moderate or severe dementia) precluding adequate understanding and/or cooperation as judged by the Investigator~4. Recurrent hypoglycaemia or hypoglycaemic unawareness as judged by the investigator~5. Previous history of severe allergy to pharmaceutical products~6. Systemic glucocorticoids users or potential users~7. Suspected type 1 diabetes (including slowly progressive insulin dependent diabetes mellitus) or positive anti-glutamic acid decarboxylase antibody~8. Any condition that the investigator considers a potential obstacle to trial participation and/or data analysis

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): None
- Glimepiride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate GSK1325760A - a Long-Term Extension Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who complete the 24-week administration of the Phase II/III study (Study No.AMB107816)~* Subjects who are assessed that the long-term extension administration of GSK1325760A is appropriate in the judgement of the investigator or subinvestigator~* Subjects who request the long-term extension administration of GSK1325760A, and agree to newly sign the informed consent form~Exclusion Criteria:~* Subjects who have been withdrawn from the Phase II/III study.~* Female subjects who wish to become pregnant.~* Treatment with other PAH medication is needed.~* A worsening of 2 or more levels of the WHO Functional Classification (see Appendix 2.1) comparing with the baseline of Phase II/III study (Study No.AMB107816).~* Worsening of right ventricular failure (e.g. as indicated by increased jugular venous pressure, new/worsened hepatomegaly, ascites, or peripheral edema) during Phase II/III study (Study No.AMB107816).~* Rapidly progressing cardiac, hepatic or renal failure during Phase II/III study (Study No.AMB107816).~* Participation to the long-term extension study is considered as inappropriate in the judgment of the investigator or subinvestigator.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1325760A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18 years or older.~* Presence of platinum-sensitive relapsed ovarian cancer.~* Treatment and treated indication according to local label SmPC and reimbursement for trabectedin and PLD treatment.~* Prior treatment with a minimum of 1 cycle of trabectedin + PLD according to SmPC before inclusion in the study, and no more than 3 previous treatment lines.~* Written informed consent indicating that patients understand the purpose and procedures and are willing to participate in the study.~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin in Intracytoplasmic Sperm Injection Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First or second trial ICSI cycle.~* Age: 20 -38 years~* BMI: patients with BMI ≥ 30 kg/m2 were advised to lose weight for 6 months through lifestyle modifications.~* AMH ≥1 ng/ml~* Basal FSH \< 10 IU/ml.~* Normal uterine cavity evidenced by HSG or office hysteroscopy~* Normal levels of prolactin and TSH before starting COS cycle~Exclusion Criteria:~* Patients with recurrent two or more failed intra-cytoplasmic sperm injection cycles.~* Uterine anomalies or Synechiae.~* Severe male factor infertility~* Patients known to have diabetes, renal, liver disease, alcoholism, or drug abuse were excluded~* Patients who were on metformin treatment were asked to have a one month washout period before study participation.~* Poor responders

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Metformin group (Type: ACTIVE_COMPARATOR): None
- Placebo group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete